Categories: News

Colin Wildey appointed Chief Risk Officer, International

LONDON, Feb. 17, 2026 /PRNewswire/ — Markel Insurance, the insurance operation within Markel Group Inc. (NYSE: MKL), today announced that Colin Wildey has been promoted to Chief Risk Officer for Markel International, subject to regulatory approval.

- Advertisement -

Wildey has been Head of Risk for Markel International since 2022, where he has played a central role in advancing the organisation’s Risk Management framework and helping the business navigate through a period of sustained, profitable growth. In his new role, he will focus on further enhancing how risk informs decision-making across the business, aligned with the organisation’s strategic ambition to put Markel ‘on the map’.

- Advertisement -

Based in London, Wildey will report to Henry Gardener, who was appointed Chief Risk Officer of Markel Insurance in 2025.

- Advertisement -

Wildey brings more than ten years of senior risk management experience across the London Market and international insurance sector. Prior to joining Markel, he was UK Chief Risk Officer and Group Head of Risk & Capital at Fidelis Insurance, responsible for the Group Risk Framework across multiple entities. Earlier in his career, he held roles in risk management, consulting and underwriting at various organisations writing business in the UK, Ireland, Bermuda, Australia and New Zealand. He has extensive experience working with regulators including the PRA, FCA, BMA and CBI.

- Advertisement -

Henry Gardener, Chief Risk Officer, Markel Insurance, said: “The Risk team at Markel International plays a critical role in strengthening resilience throughout the business, working in partnership with employees across the business to support clarity of purpose, ownership of risk and strategic alignment. By combining analytical expertise with practical insight, we help Markel meet its commitments to policyholders, regulators, shareholders and partners.

- Advertisement -

“I’m delighted to see Colin step into this new role. He has made a significant contribution to improving how risk is understood and managed across Markel International. He combines strong technical expertise with a collaborative, pragmatic approach and has built trusted relationships across underwriting, capital, actuarial, compliance and operations.”

- Advertisement -

Colin Wildey, Chief Risk Officer, Markel International, said: “Effective risk management is about helping the business take considered risks with confidence. I’m incredibly pleased about the progress we’ve made in embedding risk thinking more broadly across Markel International in recent years, and I’m looking forward to continuing to support leaders and underwriters as we navigate an increasingly complex risk environment.”

- Advertisement -

About Markel Insurance
We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide.

- Advertisement -

Logo – https://mma.prnewswire.com/media/2090808/Markel_primary_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/colin-wildey-appointed-chief-risk-officer-international-302688858.html

- Advertisement -

Recent Posts

Applied Intuition and LG Innotek Enter Strategic Partnership to Advance Autonomous Vehicle Development

OEMs will now have a faster path to production-ready autonomy using camera sensors, real-world testing…

1 hour ago

Medical AI Named First-Ever Recipient of ACC Global Digital Health Award at American College of Cardiology Annual Scientific Session

NEW ORLEANS, March 29, 2026 (GLOBE NEWSWIRE) -- Medical AI, a company specializing in artificial…

3 hours ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS)…

3 hours ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

March 28, 2026 15:00 ET  | Source: Roivant Sciences The results of the Phase 3…

3 hours ago

Organon accelerates Women’s Health progress across Asia Pacific with 2026 Her Health Grants

SYDNEY, March 30, 2026 /PRNewswire/ -- Organon Asia Pacific Cluster today announced the 2026 Her…

4 hours ago

MineScape 2026: Powered by Digital Twin and AI

BRISBANE, Australia, March 29, 2026 /PRNewswire/ -- Datamine, a trusted leader in mining software solutions,…

8 hours ago